Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Bezafibrate 100 mg
DRUG: Bezafibrate 200 mg
DRUG: Obeticholic Acid 5 mg
DRUG: Obeticholic Acid placebo
DRUG: Bezafibrate Placebo

Sponsor

Intercept Pharmaceuticals